AstraZeneca Shares Rise on Positive COPD Trial Results for Tozorakimab

AstraZeneca (LON: AZN) shares jumped 3% in early trading following the announcement of positive results from the Phase III OBERON and TITANIA trials for tozorakimab, an investigational biologic for chronic obstructive pulmonary disease (COPD). The trials demonstrated statistically significant and clinically meaningful reductions in COPD exacerbations.

The OBERON and TITANIA trials evaluated tozorakimab in patients with COPD who continued to experience exacerbations despite being on standard inhaled therapies. The studies achieved their primary endpoint, showing that tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations compared to placebo in former smokers, which was the primary population, and also in the overall population, including both former and current smokers, regardless of blood eosinophil counts or lung function severity.

Tozorakimab, a potential first-in-class monoclonal antibody targeting interleukin-33 (IL-33), uniquely inhibits the signalling of both reduced and oxidised forms of IL-33. This offers the potential to reduce inflammation and disrupt the cycle of mucus dysfunction, key drivers of COPD worsening. The drug was generally well-tolerated with a favorable safety profile.

COPD affects nearly 400 million people globally and is the third leading cause of death. Even with inhaled standard of care, over half of these patients experience exacerbations, increasing their risk of cardiopulmonary events and mortality. The positive results of tozorakimab could represent a significant advancement in COPD treatment, addressing a substantial unmet need.

Frank Sciurba, MD, FCCP, Professor of Pulmonary and Critical Care Medicine, University of Pittsburgh, and Chief Investigator of the LUNA programme, stated that the trial results suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit in a broad COPD population, independent of smoking status and eosinophilic levels.

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, highlighted that the results deliver the first two confirmatory Phase III trials for an IL-33 biologic, which is a major scientific advancement in COPD, the world’s third leading cause of death. Tozorakimab works in a fundamentally different way from other biologics, inhibiting the signalling of the reduced and oxidised forms of IL-33 to both decrease inflammation and disrupt the cycle of mucus dysfunction that are key disease drivers in COPD.

AstraZeneca’s ongoing Phase III trials of tozorakimab in COPD, PROSPERO and MIRANDA, are expected to provide further data in H1 2026. The drug is also being studied in a Phase III trial for severe viral lower respiratory tract disease and a Phase II trial in asthma, expanding its potential applications.

Analyst Summary: Bull and Bear Cases

AskTraders Takeaway: The positive trial results have injected optimism into AstraZeneca’s pipeline and could lead to revenue growth if tozorakimab is approved. Markets are reacting positively to the news, potentially setting the stage for further gains.